Compare Davita Inc (DVA) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares MSCI India ETF — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while iShares MSCI India ETF trades at $50.05. Which is the better fit depends on your goals.
| DVA | INDA | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $55.29 |
52-Week Low | $103.87 | $45.42 |
Enterprise Value | $24.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
INDA, trading at $50.39 with a 0.54% daily gain, shows a bullish technical outlook supported by moving averages, though RSI levels indicate potential overbought conditions near-term. The ETF tracks India's equity market, the world's fastest-growing large economy, which expanded 7.8% in Q1 2026 (CNBC, June 5, 2026). Recent news highlights foreign capital rotation away from AI-heavy Asian markets, with India facing sector-specific headwinds in pharmaceuticals and IT.
The outlook remains positive given India's robust economic growth, but risks include U.S. tariff uncertainty, Middle East shipping disruptions impacting exports (Reuters, August 4, 2026), and El Niño monsoon concerns. Investor sentiment is mixed amid foreign outflows, yet structural growth opportunities support long-term potential. Key watchpoints are earnings delivery from underlying holdings and macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
